Cover Image

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan

ABSTRACTBackground The aim of this study was to evaluate the public health and economic impact of the COVID-19 booster vaccination with BNT162b2 in Japan during an Omicron-dominant period from early 2022.Research design and methods A combined cohort Markov decision tree model estimated the cost-effe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mitsuhiro Nagano (Author), Kazumasa Kamei (Author), Hiroyuki Matsuda (Author), Chihiro Takahashi (Author), Jingyan Yang (Author), Koji Wada (Author), Naohiro Yonemoto (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023)

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
by: Masayoshi Shinjoh, et al.
Published: (2024)

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024)

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024)

Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022)

Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
by: Jenan Ahmed Al-Matouq, et al.
Published: (2022)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
by: Chi-Yan Lam, et al.
Published: (2023)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
by: Toshio Naito, et al.
Published: (2022)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
by: Moe H. Kyaw, et al.
Published: (2023)

Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron
by: Manuela Di Fusco, et al.
Published: (2023)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
by: Suvimol Niyomnaitham, et al.
Published: (2022)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
by: Francesca Fortunato, et al.
Published: (2023)

BNT162b2 mRNA Vaccine-Induced Immune Response in Oral Fluids and Serum
by: Chaminda Jayampath Seneviratne, et al.
Published: (2023)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
by: Gili Regev-Yochay, et al.
Published: (2021)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer-BioNTech) COVID‐19 vaccination
by: Akihiro Matsubara, et al.
Published: (2021)

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
by: Shanti Pather, et al.
Published: (2023)

A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome
by: Yoshihiro Matsuda, et al.
Published: (2023)

Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty
by: Suvimol Niyomnaitham, et al.
Published: (2024)

B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
by: Younes Bathish, et al.
Published: (2024)

Effectiveness of BNT162b2 COVID-19 vaccine among healthcare workers of a large hospital, Milan, Italy
by: Dario Consonni, et al.
Published: (2022)

Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study
by: Sami Abdeen, et al.
Published: (2024)

Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases
by: Richard Paul Junghans
Published: (2021)

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data
by: Frank van den Ouweland, et al.
Published: (2024)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
by: Rana Shibli, et al.
Published: (2021)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021)

Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years
by: Enagnon Kazali Alidjinou, et al.
Published: (2022)

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024)

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study
by: Angel Paternina-Caicedo, et al.
Published: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
by: Ai-Min Hui, et al.
Published: (2022)

Allergy to PEG (polyethylene glycol) - sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
by: Bernadette Eberlein, et al.
Published: (2024)

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
by: Salvatore Zaffina, et al.
Published: (2021)

Coincidence of BNT162b2 mRNA COVID-19 vaccination and hashimoto thyroiditis presenting as atrioventricular block: Causality or casualty
by: Kuang-Jen Chien, et al.
Published: (2023)

Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes
by: Hamdi Cihan Emeksiz, et al.
Published: (2023)

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
by: Rachael K. Raw, et al.
Published: (2023)

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine.
by: Rachael K Raw, et al.
Published: (2023)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
by: Xiaotian Wu, MBBS, MRCP, MMed, et al.
Published: (2022)

Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis
by: Tingting Li, et al.
Published: (2022)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
by: Andrea Lombardi, et al.
Published: (2021)

Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
by: Clara Udaondo, et al.
Published: (2022)